Subscribe to ExpertReview

The latest research, meeting updates and CME, in your inbox.

Singapore · Research

Preservative‑free hyaluronic acid superior in dry eye management

Human idea, AI creation20 Nov 2026Ophthalmology
Share

A six‑month randomised trial shows preservative‑free hyaluronic acid yields greater symptom relief and fewer drops than a benzalkonium chloride–preserved product in dry eye disease.

Graph comparing dry eye symptom scores: preservative‑free hyaluronic acid vs benzalkonium chloride drop
Image: human idea, AI creation

Introduction

Dry eye disease (DED) remains a common indication for artificial tears, yet the preservative content of these preparations may influence ocular surface health. Recent experimental data suggest benzalkonium chloride (BAK) can induce toxicity on the corneal and conjunctival epithelium, potentially diminishing therapeutic benefit. This article summarises a prospective, single‑masked randomised controlled trial in patients with symptomatic DED that directly compared a preservative‑free hyaluronic acid solution (PF HA) with one preserved with BAK (BAK HA).

Methods

The study recruited 47 adults with a confirmed diagnosis of DED, randomising them to either PF HA or BAK HA for six months. Both groups received identical formulations except for the preservative; the study was single‑masked, with patients unaware of their allocation. The main endpoint was the shift in symptom burden, scored by OSDI (Ocular Surface Disease Index), between baseline and month 6. Secondary endpoints were instillation frequency, best‑corrected visual acuity (BCVA), tear volume (Schirmer I), tear stability (non‑invasive break‑up time, NIBUT; fluorescein break‑up time, TBUT) and ocular surface staining (corneal fluorescein, FCS; conjunctival lissamine green, LCS). Mixed‑effects models were used for continuous variables and mixed‑effects ordinal logistic regression for ordinal data.

Results

Forty‑three participants completed the trial (PF HA n=22; BAK HA n=21). OSDI scores fell more with PF HA (14.36 points) than with BAK HA (9.42 points); adjusted values, between‑group P = 0.001. At the final visit, about 40 % of patients on PF HA had normal OSDI scores (≤12); in the BAK HA arm, nobody did. At month 6, the groups did not differ significantly on BCVA, FCS, LCS, NIBUT, Schirmer I or TBUT. Over time, PF HA showed a more favourable course in symptoms and selected signs, with significant treatment‑by‑time effects for LCS (P < 0.001), FCS (P = 0.002), NIBUT (P = 0.017) and OSDI (P < 0.001). Importantly, instillation frequency was lower in the PF HA group (P < 0.001), indicating potential ease of use and improved adherence.

Discussion

Both preservative‑free and BAK‑preserved hyaluronic acid formulations improved signs and symptoms of DED. However, PF HA conferred superior symptomatic relief, a greater proportion of patients with normal OSDI scores, and reduced instillation frequency. These findings align with pre‑clinical evidence of BAK‑induced ocular surface toxicity and support a clinical preference for preservative‑free preparations in chronic DED management.

Clinical Implications

When long‑term therapy is required for DED, clinicians should consider preservative‑free hyaluronic acid as the first‑line choice, particularly for patients with severe or persistent symptoms. The reduced instillation burden may translate into better compliance. Future studies should evaluate whether these benefits persist beyond six months and assess cost‑effectiveness in routine practice.


References

  1. Bucsan R, Chua J, Chi L, Deleanu D, Totir M, Coroleuca R, et al. Randomized Single-Masked Study of Preservative-Free Versus Preserved Hyaluronic Acid in Dry Eye Disease. Transl Vis Sci Technol. 2026;15(11):6. doi:10.1167/tvst.15.11.6. PMID: 42986170. PubMed

Medically reviewed by Stijn van den Borne on 20 Nov 2026